| Anthony Tufaro, MD, DDS | |
|
9500 Euclid Ave # A60, Cleveland, OH 44195-5417 | |
| (216) 444-2501 | |
| (216) 444-9419 |
| Full Name | Anthony Tufaro |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 31 Years |
| Location | 9500 Euclid Ave # A60, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477506798 | NPI | - | NPPES |
| 556100100 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | D53606 (Maryland) | Secondary |
| 208200000X | Plastic Surgery | 35.142873 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
Researchers at NYU Langone Medical Center and elsewhere say that a vaccination they have developed to fight a brain-based, wasting syndrome among deer and other animals may hold promise on two additional fronts: Protecting U.S. livestock from contracting the disease, and preventing similar brain infections in humans.
In September, a ban on triclosan in over-the-counter antiseptic soaps, gels and wipes went into effect in the U.S. But the antibacterial ingredient is still allowed in toothpastes for its reported ability to reduce gum inflammation, plaque and cavities.
Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
› Verified 5 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
Researchers at NYU Langone Medical Center and elsewhere say that a vaccination they have developed to fight a brain-based, wasting syndrome among deer and other animals may hold promise on two additional fronts: Protecting U.S. livestock from contracting the disease, and preventing similar brain infections in humans.
In September, a ban on triclosan in over-the-counter antiseptic soaps, gels and wipes went into effect in the U.S. But the antibacterial ingredient is still allowed in toothpastes for its reported ability to reduce gum inflammation, plaque and cavities.
Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
› Verified 5 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
Researchers at NYU Langone Medical Center and elsewhere say that a vaccination they have developed to fight a brain-based, wasting syndrome among deer and other animals may hold promise on two additional fronts: Protecting U.S. livestock from contracting the disease, and preventing similar brain infections in humans.
In September, a ban on triclosan in over-the-counter antiseptic soaps, gels and wipes went into effect in the U.S. But the antibacterial ingredient is still allowed in toothpastes for its reported ability to reduce gum inflammation, plaque and cavities.
Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony Tufaro, MD, DDS 800 Stanton L Young Blvd Ste 8300, Oklahoma City, OK 73104-5018 Ph: (405) 271-2220 | Anthony Tufaro, MD, DDS 9500 Euclid Ave # A60, Cleveland, OH 44195-5417 Ph: (216) 444-2501 |
News Archive
Researchers at NYU Langone Medical Center and elsewhere say that a vaccination they have developed to fight a brain-based, wasting syndrome among deer and other animals may hold promise on two additional fronts: Protecting U.S. livestock from contracting the disease, and preventing similar brain infections in humans.
In September, a ban on triclosan in over-the-counter antiseptic soaps, gels and wipes went into effect in the U.S. But the antibacterial ingredient is still allowed in toothpastes for its reported ability to reduce gum inflammation, plaque and cavities.
Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
› Verified 5 days ago
David Rowe, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Fatma Betul Tuncer, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-2200 Fax: 216-444-9419 | |
Isaac B James, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-445-4724 | |
Dr. Bahar Bassiri Gharb, M.D., PHD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, A60, Cleveland, OH 44195 Phone: 502-377-3424 | |
Dr. Kyle James Chepla, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-4450 | |
Daniel A. Medalie, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Randall J Yetman, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 800-223-2273 |